Ritalin La

Narcolepsy, Attention Deficit Hyperactivity Disorder

Treatment

20 Active Studies for Ritalin La

What is Ritalin La

Methylphenidate

The Generic name of this drug

Treatment Summary

Dexmethylphenidate is a stimulant drug used to treat Attention Deficit Hyperactivity Disorder (ADHD). Approved in 2002, it works by blocking the reuptake of norepinephrine and dopamine in the brain, making it more available for use. It is believed that the “right-handed” version of this drug is more effective and produces fewer side effects than its “left-handed” version or the combination of both.

Methylphenidate Hydrochloride

is the brand name

Ritalin La Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Methylphenidate Hydrochloride

Methylphenidate

1955

490

Effectiveness

How Ritalin La Affects Patients

Dexmethylphenidate is a form of the drug methylphenidate that is more potent than the regular version. It works by blocking the reuptake of norepinephrine and dopamine in the brain.

How Ritalin La works in the body

Methylphenidate works by blocking the reuptake of dopamine and norepinephrine in the brain, specifically in the thalamus and striatum. Studies have shown that it can also affect the prefrontal cortex, although this effect is not as strong. When taken, it also affects blood flow to areas of the brain like the striatum, supplementary motor area, and posterior parietal cortex.

When to interrupt dosage

The prescribed dosage of Ritalin La is contingent upon the diagnosed condition. The amount of dosage alters, according to the method of administration (e.g. Tablet, film coated, extended release or Capsule, extended release) outlined in the table beneath.

Condition

Dosage

Administration

Attention Deficit Hyperactivity Disorder

20.0 mg, , 30.0 mg, 40.0 mg, 10.0 mg, 60.0 mg, 27.0 mg, 36.0 mg, 54.0 mg, 50.0 mg, 5.0 mg, 2.5 mg, 5.0 mg/mL, 10.0 mg/mL, 18.0 mg, 80.0 mg, 15.0 mg, 10.0 mg/hour, 20.0 mg/hour, 15.0 mg/hour, 30.0 mg/hour, 30.0 mg/mL, 6.0 mg/mL, 7.5 mg/mL, 9.0 mg/mL, 8.6 mg, 25.9 mg, 17.3 mg, 1.0 mg/mL, 2.0 mg/mL, 25.0 mg, 35.0 mg, 55.0 mg, 70.0 mg, 85.0 mg, 100.0 mg, 45.0 mg, 72.0 mg, 63.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, chewable, Tablet, chewable - Oral, Solution, Solution - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Chewable, Extended Release, Tablet, Chewable, Extended Release - Oral, Transdermal, Patch, Patch - Transdermal, Suspension, extended release, Suspension, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral

Narcolepsy

20.0 mg, , 30.0 mg, 40.0 mg, 10.0 mg, 60.0 mg, 27.0 mg, 36.0 mg, 54.0 mg, 50.0 mg, 5.0 mg, 2.5 mg, 5.0 mg/mL, 10.0 mg/mL, 18.0 mg, 80.0 mg, 15.0 mg, 10.0 mg/hour, 20.0 mg/hour, 15.0 mg/hour, 30.0 mg/hour, 30.0 mg/mL, 6.0 mg/mL, 7.5 mg/mL, 9.0 mg/mL, 8.6 mg, 25.9 mg, 17.3 mg, 1.0 mg/mL, 2.0 mg/mL, 25.0 mg, 35.0 mg, 55.0 mg, 70.0 mg, 85.0 mg, 100.0 mg, 45.0 mg, 72.0 mg, 63.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, chewable, Tablet, chewable - Oral, Solution, Solution - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Chewable, Extended Release, Tablet, Chewable, Extended Release - Oral, Transdermal, Patch, Patch - Transdermal, Suspension, extended release, Suspension, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral

Warnings

Ritalin La has nine contraindications and should not be consumed in combination with the conditions provided in the subsequent table.

Ritalin La Contraindications

Condition

Risk Level

Notes

advanced arteriosclerosis

Do Not Combine

Gilles de la Tourette syndrome

Do Not Combine

Thyrotoxicosis

Do Not Combine

Pulse Frequency

Do Not Combine

Open-angle glaucoma

Do Not Combine

Hypertensive disease

Do Not Combine

Pulse Frequency

Do Not Combine

Tension-Type Headache

Do Not Combine

Generalized Anxiety Disorder

Do Not Combine

symptomatic cardiovascular disease

Do Not Combine

Tourette Syndrome

Do Not Combine

Pheochromocytoma

Do Not Combine

Tics

Do Not Combine

Agitation

Do Not Combine

There are 20 known major drug interactions with Ritalin La.

Common Ritalin La Drug Interactions

Drug Name

Risk Level

Description

Desflurane

Major

Methylphenidate may increase the hypertensive activities of Desflurane.

Diethyl ether

Major

Methylphenidate may increase the hypertensive activities of Diethyl ether.

Enflurane

Major

Methylphenidate may increase the hypertensive activities of Enflurane.

Halothane

Major

Methylphenidate may increase the hypertensive activities of Halothane.

Isoflurane

Major

Methylphenidate may increase the hypertensive activities of Isoflurane.

Ritalin La Toxicity & Overdose Risk

There is no difference in the effects of dexmethylphenidate between genders. There have not been many studies done on the difference in effects of this drug across racial groups, young children, those with kidney or liver impairment, pregnant women, or elderly patients. People with kidney problems are unlikely to need to adjust their dose, as the drug isn't processed through the kidneys. Animal studies have shown that taking this drug during pregnancy can cause delayed development and reduced weight gain in male offspring. When weighing the benefits and risks of taking this drug, it is important to note that it has not been linked to cancer, but has caused liver tumors in mice

Ritalin La Novel Uses: Which Conditions Have a Clinical Trial Featuring Ritalin La?

77 active clinical trials are presently underway to evaluate the potential of Ritalin La to treat Attention Deficit Hyperactivity Disorder.

Condition

Clinical Trials

Trial Phases

Attention Deficit Hyperactivity Disorder

63 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Narcolepsy

2 Actively Recruiting

Not Applicable, Phase 1

Ritalin La Reviews: What are patients saying about Ritalin La?

5

Patient Review

6/10/2012

Ritalin La for Attention Deficit Disorder with Hyperactivity

My symptoms come back in the afternoon and evening.

5

Patient Review

7/25/2009

Ritalin La for Attention Deficit Disorder with Hyperactivity

5

Patient Review

3/3/2010

Ritalin La for Attention Deficit Disorder with Hyperactivity

Ritalin LA has been a godsend for my narcolepsy. I've tried other medications like Provigil in the past, but they either didn't work or had terrible side effects. Ritalin LA helps me get through the day without feeling exhausted all the time.

4.3

Patient Review

2/26/2015

Ritalin La for Attention Deficit Disorder with Hyperactivity

I started taking this in grade three, and then switched to concerta. Big mistake- I got very aggressive and territorial. I attacked my sister for no reason and got angry over small things like food not being perfect. This is the complete opposite of me. Then, I switched back to ritalin and everything has been good. I still get C grades but they're a lot better when on ritalin.

4.3

Patient Review

4/14/2013

Ritalin La for Attention Deficit Disorder with Hyperactivity

This medication helped me to finally be able to focus and finish tasks that I had started.

4

Patient Review

7/29/2015

Ritalin La for Attention Deficit Disorder with Hyperactivity

I just started taking IC Methylphenidate today. So far, I haven't noticed any negative side effects. I was previously taking 54 mg of Concerta, but the cost was too high.

4

Patient Review

9/13/2009

Ritalin La for Attention Deficit Disorder with Hyperactivity

3.7

Patient Review

2/24/2011

Ritalin La for Attention Deficit Disorder with Hyperactivity

I have been experiencing chest pains that occur approximately 15-20 minutes after taking Ritalin LA.

3.3

Patient Review

2/2/2010

Ritalin La for Attention Deficit Disorder with Hyperactivity

3

Patient Review

9/23/2010

Ritalin La for Attention Deficit Disorder with Hyperactivity

I'm looking for a cheaper alternative to Ritalin that works just as well or similarly.

2.7

Patient Review

5/1/2011

Ritalin La for Attention Deficit Disorder with Hyperactivity

I have been experiencing chest pains that onset approx. within 15-20 minutes after taking ritalin LA is there anyone who can give me some advice in this situation????

2

Patient Review

1/27/2014

Ritalin La for Attention Deficit Disorder with Hyperactivity

I have ADD and this treatment didn't help me at all.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ritalin la

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long is Ritalin LA effective?

").

Ritalin LA is designed to release half of the medication immediately and the other half after four hours, providing up to nine hours of relief with a single dose regardless of whether or not the patient has eaten."

Answered by AI

Is Ritalin LA better than Ritalin?

"Ritalin SR and Ritalin LA enter the bloodstream more slowly than standard Ritalin, providing 4-8 hours and 10 hours of symptom relief respectively."

Answered by AI

What does LA mean in Ritalin?

"Ritalin LA (long-acting) capsules are for treating Attention Deficit Hyperactivity Disorder (ADHD). Ritalin LA is a stimulant that makes people with ADHD more attentive and less impulsive and hyperactive."

Answered by AI

Is Ritalin LA still available?

"In a letter dated March 23, 2016, Novartis notified the FDA that RITALIN LA (methylphenidate hydrochloride) extended-release capsules, 60 mg, were being discontinued, and the FDA moved the drug product to the “Discontinued Drug Product List” section of the Orange Book."

Answered by AI

Clinical Trials for Ritalin La

Image of Seattle Children's Hospital in Seattle, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Seattle, WA

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Seattle Children's Hospital

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Have you considered Ritalin La clinical trials?

We made a collection of clinical trials featuring Ritalin La, we think they might fit your search criteria.
Go to Trials
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA

The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.

Waitlist Available
Has No Placebo

The University of Iowa

Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)

Recruiting
Device

UCSF Nancy Friend Pritzker Psychiatry Building

Image of The University of Texas at Austin in Austin, United States.

Transcranial Photobiomodulation for ADHD

18 - 44
All Sexes
Austin, TX

The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.

Waitlist Available
Online Trial

The University of Texas at Austin

Have you considered Ritalin La clinical trials?

We made a collection of clinical trials featuring Ritalin La, we think they might fit your search criteria.
Go to Trials
Image of Louisiana State University in Baton Rouge, United States.

Virtual Reality for ADHD

18 - 25
All Sexes
Baton Rouge, LA

The goal of this larger parallel group randomized trial is to test the impact of a virtual reality program for improving the ability of emerging adults (age 18-25) with attention deficit hyperactivity disorder (ADHD) to stay focused while completing homework and studying. This study compares the impact of using a virtual reality headset to using a virtual reality headset while also receiving feedback about levels of focus to a control group. The main question is whether participants demonstrate significantly improved concentration while completing homework and studying in virtual reality and whether they enjoy and prefer working in a virtual reality environment. Concentration is measured both through participant report and also using keyboard and mouse click data to assess work productivity objectively.

Phase 4
Waitlist Available

Louisiana State University (+1 Sites)

Joshua M Langberg, PhD

Image of Duke University in Durham, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Durham, NC

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Duke University

John Mitchell, PhD

Image of Kennedy Krieger Institute in Baltimore, United States.

Iron Supplementation for ADHD and Restless Sleep

8 - 18
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn if iron supplementation works to restless sleep in youth with ADHD. A second goal is to learn if iron supplementation helps to ease ADHD symptoms. The main questions that this trial aims to answer are: Does 3 months of iron supplementation treatment improve parent- and youth self-reported sleep difficulties more than placebo? Does 3 months of iron supplementation treatment improve sleep as measured by actigraphy more than placebo? Does 3 months of iron supplementation treatment improve parent-reported and/or objectively measured attention more than placebo? Researchers will compare over-the-counter iron supplementation treatment to a placebo (a look-alike substance that contains no drug) to see if iron supplementation works to treat sleep difficulties in youth with ADHD. Participants will: * Take iron supplements every day for 3 months * Visit the clinic once before treatment begins and once at the end of treatment to complete tests and rating scales related to sleep and attention * Wear motion-monitoring leg bands while sleeping for one 2-week period before treatment begins and one 2-week period at the end of treatment

Phase 1 & 2
Waitlist Available

Kennedy Krieger Institute

Alison E Pritchard, PhD

Image of Montana State University in Bozeman, United States.

Speech-Gesture Combinations for Autism

Any Age
All Sexes
Bozeman, MT

This research study investigates how hand gestures can support language comprehension and communication skills of hearing speaking, non-speaking, and/or minimally verbal individuals with Autism Spectrum Disorders (ASD), who are especially disadvantaged by the lack of accessible services in their rural communities. Individuals with other cognitive profiles, including Developmental Language Disorder (DLD), ADHD, Dyslexia, and others are welcome too. The study uses methods of eye tracking and recording of brain activity to understand how hand gestures adapted from signs from American Sign Language, such as \[cry\], can promote successful understanding of words like "cry". The overarching goal is to help families effectively utilize gestures to support communication with their children.

Recruiting
Has No Placebo

Montana State University

Have you considered Ritalin La clinical trials?

We made a collection of clinical trials featuring Ritalin La, we think they might fit your search criteria.
Go to Trials